Navigation Links
Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
Date:12/6/2008

/p>

The Potential for EXPAREL

EXPAREL is a novel formulation of bupivacaine designed to provide effective, safe, prolonged (72 hours) postoperative pain relief in a single administration. Currently available local anesthetics typically have short (about 6 to 8 hours) duration of action resulting in limited pain relief in the first few days following surgery when pain is the most intense.

"The results of this study clearly demonstrate the potential of EXPAREL in fulfilling this unmet need," said Ronald Burch, M.D, PhD, Chief Medical Officer, Pacira. "EXPAREL represents an important advance in pain control that allows for extended delivery of bupivacaine, a well-characterized analgesic with a long-established efficacy and safety record. We look forward to sharing the results of multiple phase II and III clinical trials across a broad range of surgical procedures."

EXPAREL, currently in late Phase III clinical development, is being studied in several different types of surgical procedures where postoperative pain management is especially problematic. It is the latest product to benefit from Pacira Pharmaceutical's proprietary sustained-release DepoFoam(R) technology. DepoFoam technology is designed to address the limitations of widely known and used drugs by enhancing their dosing and/or administration profile. It achieves this by encapsulating the drug in multivesicular liposomal particles which then release the drug over a desired period of time without altering the drug molecule. DepoFoam is a proven technology that is already used in two commercially available products in the U.S. and Europe.

About Pacira

Pacira Pharmaceuticals, Inc. is an acute care specialty pharmaceutical company founded in March, 2007 through the acquisition of the former SkyePharma PLC injectable business, for which an experienced management team was assembled to address the needs of
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
2. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
3. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
6. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
(Date:7/6/2015)... DIEGO , July 6, 2015  OncoSec Medical ... DNA-based intratumoral cancer immunotherapies, today announced the appointment of ... position of Vice President of Market Development, effective July ... responsible for evaluating, designing, and executing on the company,s ... "I,m very excited to welcome Joann to ...
(Date:7/5/2015)... 2015 Nihon University is pleased to ... Medical-Engineering Collaboration "Medicine Definitely Jumps Up with 8K" ... Tokyo, Japan . Many experts ... will present their achievements and future prospects on ... produced with 8K technology. (Documentation: ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3
... CSG/SportsCoatings,today announced approximately 10 million square feet of ... coating, TurfAide(TM),in 2008 -- up from 1.5 million ... in demand for TurfAide has been attributed to,several ... of the American,Medical Association that found MRSA (methicillin-resistant ...
... Very Low Dose Glucagon ahead of Phase 2 Clinical Trials in ... ... Jan. 8 DiObex, Inc., a privately held,biotechnology company developing treatments for ... U.S. Patent,and Trademark Office for the use of very low dose glucagon, ...
Cached Medicine Technology:10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide 2DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... Spa industries, announces the return of its complimentary educational webinar series ... medical business leaders creates success for their clients through targeted marketing, sales, digital ...
(Date:7/6/2015)... Beach, Virginia (PRWEB) , ... July 06, 2015 ... ... States choose fat-reduction procedures each year for aesthetic reasons, which is why liposuction ... country. For a particular demographic, however, fat reduction has become more than a ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud to announce ... Teaching Award on behalf of the department of Family Practice. , “This award is ... be practicing in. The technology is changing so rapidly and we are also developing ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global ... executive management team. Most recently, Jowers held the position as Director of the Hinckley ... After spending a decade building the institute, Jowers states that he was ready for ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with ... survived the same cancer. , “Receiving a cancer diagnosis is often the most ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2
... UPTON, NY - A new study by scientists at the ... Norway suggests that the benefits of moderately increased exposure to ... against the lethal effects of many forms of cancer and ... cancer in populations deficient in vitamin D. The study will ...
... activate abnormally in malignant cells , , MONDAY, Jan. 7 (HealthDay ... genes that play a role in cell division, and ... of those genes show an abnormal pattern of activation in ... issue of the Proceedings of the National Academy of ...
... University Center for Clinical and Translational Science (CCTS) has ... Eight Rockefeller researchers will each receive $25,000 from the ... if successful, might lead to clinical trials. The CCTS ... established through funds from a Clinical and Translational Science ...
... caused by aging, can also be caused by pesticides ... that trichloroethylene (TCE) is a risk factor for parkinsonism, ... Parkinsons disease. TCE is a chemical widely used in ... water and soil due to runoff from manufacturing sites ...
... experts are split on the need for supplements , , MONDAY, ... D -- sourced through sunlight, some foods and supplements ... such as heart attack and stroke, U.S. researchers report. , ... Heart Study included 1,739 people, average age 59, living in ...
... suffering from a form of asphyxia at birth have ... a lifetime of debilitating and costly health complications, according ... , The findings, which appear today in the January ... technique, that better availability and placement of CoolCaps within ...
Cached Medicine News:Health News:More sun exposure may be good for some people 2Health News:More sun exposure may be good for some people 3Health News:Team Finds 118 Genes That Might Play Role in Cancer 2Health News:Rockefeller University's Center for Clinical and Translational Science funds pilot studies 2Health News:Trichloroethylene is a risk factor for parkinsonism 2Health News:Trichloroethylene is a risk factor for parkinsonism 3Health News:Low Vitamin D Linked to Heart Risk 2Health News:Low Vitamin D Linked to Heart Risk 3Health News:Better access to cool caps improves outcomes, lowers cost of treating asphyxia in newborns 2
... an enzymatic cleanser for automated and semi-automated ... 475ml bottle has a flip-top spout for ... that require manual addition of an enzyme ... of this product. The shelf life of ...
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... is a nucleated red blood cell (nRBC) control ... Coulter LH 750/LH 755 hematology analyzer in its ... for the Coulter LH 750/LH 755. nRBC-Chex for ... cap-pierceable vials. nRBC-Chex for LH has a 75-day ...
Medicine Products: